Exact Mass: 630.3074
Exact Mass Matches: 630.3074
Found 316 metabolites which its exact mass value is equals to given mass value 630.3074
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Remikiren
Remikiren is only found in individuals that have used or taken this drug. It is an orally active, high specificity renin inhibitor. Several in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09X - Other agents acting on the renin-angiotensin system > C09XA - Renin-inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
(R)-6'-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin
(R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is found in citrus. (R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is a constituent of Citrus hassaku juice oil. Constituent of Citrus hassaku juice oil. (R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is found in citrus.
Brassica napus non-fluorescent chlorophyll catabolite 3
Brassica napus non-fluorescent chlorophyll catabolite 3 is found in brassicas. Brassica napus non-fluorescent chlorophyll catabolite 3 is isolated from rape cotyledons. Isolated from rape cotyledons. Brassica napus non-fluorescent chlorophyll catabolite 3 is found in brassicas.
Gambogenic Acid
Caspase-1 Inhibitor VI
PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0)
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Nonioside B
Constituent of the fruit of Indian mulberry (Morinda citrifolia), a plant eaten as a famine food and occasionally as a staple in the Pacific region [DFC]. Nonioside B is found in fruits.
Ddabvi
9-Dihydro-13-acetylbaccatin III is a natural product found in Taxus wallichiana with data available. 9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations. IC50 value: Target: There are a series of closely related natural organic compounds isolated from the Pacific yew tree (Taxus brevifolia) and related species. Taxols have exhibit antitumor agents. 9-Dihydro-13-acetylbaccatin III is an antineoplastic agent and an anti-cancer intermediate. 9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations. IC50 value: Target: There are a series of closely related natural organic compounds isolated from the Pacific yew tree (Taxus brevifolia) and related species. Taxols have exhibit antitumor agents. 9-Dihydro-13-acetylbaccatin III is an antineoplastic agent and an anti-cancer intermediate.
gambogenic acid
Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1]. Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1].
Gambogenic
Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1]. Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1].
13-Acetyl-9-dihydrobaccatin III
9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations. IC50 value: Target: There are a series of closely related natural organic compounds isolated from the Pacific yew tree (Taxus brevifolia) and related species. Taxols have exhibit antitumor agents. 9-Dihydro-13-acetylbaccatin III is an antineoplastic agent and an anti-cancer intermediate. 9-Dihydro-13-acetylbaccatin III (9-DHAB III) is an intermediate for taxol analog preparations. IC50 value: Target: There are a series of closely related natural organic compounds isolated from the Pacific yew tree (Taxus brevifolia) and related species. Taxols have exhibit antitumor agents. 9-Dihydro-13-acetylbaccatin III is an antineoplastic agent and an anti-cancer intermediate.
Peridinin
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids Window width to select the precursor ion was 3 Da.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 20 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 10 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.
dimethyl 2,3-bis[5-(3,7-dimethylocta-2,6-dienyl)-3,6-dioxocyclohexa-1,4-dienyl]succinate|lettowiaquinone
3,3-(3-ethylidene-16-hydroxy-2,7,13,17-tetramethyl-1,19-dioxo-18-vinyl-1,2,3,15,16,19,22,24-octahydro-21H-biline-8,12-diyl)-bis-propionic acid dimethyl ester|Aplysioviolin
16beta,17-dihydroxy-ent-kauran-19-oic acid 19-[alpha-L-arabinopyranosyl-(1->2)-beta-D-glucopyranosyl] ester
12-(deca-2,4-dienoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one|EBI-61
(-)-(2S,3S,4R)-10-de-O-carbamoyl-12-O-carbamoylstreptothricin E|Streptothricin-E
1-O-[2-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-acetoxy-(2E,6E)-farnesol|crenulatoside F
1-O-[2,3-di-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-hydroxy-(2E,6E)-farnesol|crenulatoside E
Hybrimycin A1|Hybrimycin A2|Hybrimycin B1|Hybrimycin B2
(2alpha,4alpha,5alpha,7beta,9beta,10beta)-11(15-1)-Abeo-2,20-epoxy-11-taxene-4,5,7,9,10,13,15-heptol
2-hydroxyacetic acid rel-(1aR,4R,5R,5aS,7R,9R,9aR,10S,11R,11aS)-9,10-bis(acetyloxy)-5-(benzoyloxy)dodecahydro-4,7-dihydroxy-1a,9a,12,12-tetramethyl-6-methylene-2-oxo-3H-4,11a-methanobenzo[5,6]cyclodec[1,2-b]oxiren-11-yl ester|rel-(2alpha,5alpha,7beta,9alpha,10beta,12alpha)-7,9-bis(acetyloxy)-2-(benzoyloxy)-11,12-epoxy-1,5-dihydroxy-10-[(hydroxyacetyl)oxy]tax-4(20)-en-13-one
(22R)-27-hydroxy-7alpha-methoxy-1-oxowitha-3,5,24-trienolide 27-O-beta-D-glucopyranoside
2,6-di(O-beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose|2,6-di-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose|nonioside B
Me glycoside,2,3,4-tri-Ac-,3,4-dibenzyl-2-O-alpha-L-Rhamnopyranosyl-L-rhamnose
1-O-[3-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-acetoxy-(2E,6E)-farnesol|crenulatoside G
His Arg Tyr Arg
Tyr His Arg Arg
His Arg Arg Tyr
His Tyr Arg Arg
Asn Arg Arg Trp
Asn Arg Trp Arg
Asn Trp Arg Arg
Arg His Arg Tyr
Arg His Tyr Arg
Arg Asn Arg Trp
Arg Asn Trp Arg
Arg Arg His Tyr
Arg Arg Asn Trp
Arg Arg Trp Asn
Arg Arg Tyr His
Arg Trp Asn Arg
Arg Trp Arg Asn
Arg Tyr His Arg
Arg Tyr Arg His
Trp Asn Arg Arg
Trp Arg Asn Arg
Trp Arg Arg Asn
Tyr Arg His Arg
Tyr Arg Arg His
(R)-6-O-(4-Geranyloxy-2-hydroxy)-cinnamoylmarmin
Brassica napus non-fluorescent chlorophyll catabolite 3
Nor-peridinin1
Nor-peridinin2
2-[3-[5,5-dimethyl-3-[4-(1,3,3-trimethylindol-1-ium-2-yl)but-3-en-2-ylidene]cyclohexen-1-yl]but-2-enylidene]-1,3,3-trimethylindole,perchlorate
5,5,6,6,7,7,8,8-Octahydro-1,1-binaphthalene-2,2-diylbis(dip henylphosphine)
3-Ethyl-2-[3-(3-ethyl-1,3-dihydro-1,1-dimethyl-2H-benz[e]indol-2-ylidene)-1-propen-1-yl]-1,1-dimethyl-1H-benz[e]indolium hexafluorophosphate(1-) (1:1)
L-Urobilin
L-Urobilin or Stercobilin is a byproduct of bilirubin degradation. It is a tetrapyrrole chemical compound, responsible for the typical brown color of human feces. It is created by bacterial action on bilirubin and subsequent oxidation. In plasma virtually all the bilirubin is tightly bound to plasma proteins, largely albumin, because it is only sparingly soluble in aqueous solutions at physiological pH. In the sinusoids unconjugated bilirubin dissocates from albumin, enters the liver cells across the cell membrane through non-ionic diffusion to the smooth endoplasmatic reticulum, where it is converted to a water-soluble ester glucuronide by bilirubin UDP-glucuronyl transferase. Following conjugation, bilirubin is transferred rapidly across the canalicular membrane into the bile canaliculi. In the intestinal tract bilirubin is reduced to urobilinogen, which is subsequently reabsorbed to some extent into the enterohepatic circulation, removed from plasma by the liver and excreted unchanged in the bile. The residual part of urobilinogen is further reduced to urobilin, stercobilin and dipyrrolmethenes and excreted in the feces. [HMDB]
3-Hydroxy-4-methyl-anthranilate pentapeptide lactone
12-Ethyl-71-hydroxy-8-propylbacteriochlorophyllide c
(-)-(2S,3S,4R)-10-de-O-carbamoyl-12-O-carbamoylstreptothricin E
A natural product found in Streptomyces sp. I08A 1776.
N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(1-oxo-2-phenylethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-(2-aminophenyl)-4-[[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-9-[[oxo-(propan-2-ylamino)methyl]amino]-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl-methylamino]methyl]benzamide
[(2R,3S,4S,5R,6R)-6-[(2S,3S,4R)-2-formamido-3,4-dihydroxy-15-methylhexadecoxy]-3,4,5-trihydroxyoxan-2-yl]methyl 2-(methylazaniumyl)ethyl phosphate
[(2R,3S,4S,5R,6R)-6-[(2S,3S,4R)-2-formamido-3,4-dihydroxy-15-methylhexadecoxy]-3,4,5-trihydroxyoxan-2-yl]methyl 2-(methylamino)ethyl hydrogen phosphate
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3R)-3-ethyl-2-(2-hydroxyethyl)-1,2,3,4-tetrahydroindolo[2,3-a]quinolizin-7-yl]propanoate
Remikiren
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09X - Other agents acting on the renin-angiotensin system > C09XA - Renin-inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Z-YVAD-FMK
Z-YVAD-FMK is a?cell-permeable?caspase-1 and -4 inhibitor with?anti-inflammatory and anti-tumor activities[1].
n-{1-[1,15-dihydroxy-3-methoxy-12-(4-methoxyphenyl)-13-phenyl-5,7,11-trioxatetracyclo[10.2.1.0²,¹⁰.0⁴,⁸]pentadeca-2,4(8),9-triene-14-carbonyl]pyrrolidin-2-yl}-2-methylpropanimidic acid
n-{1-[(2r,5s,6r)-5-{[(2r,3r,4s,5s,6r)-5-(dimethylamino)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-4-[(4r)-4-(hydroxymethyl)-4-methyl-5-oxoimidazolidin-1-yl]benzamide
18-ethyl-6,12-dihydroxy-4-(4-hydroxyphenyl)-7-(1h-indol-3-ylmethyl)-8,10,13,15,17-pentamethyl-1-oxa-5,8,11-triazacyclooctadeca-5,11,15-triene-2,9-dione
(2r)-n-[(2r)-1-[(1r,9r,10r,11s,12r)-1,12-dihydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-11-phenyl-8-oxatricyclo[7.2.1.0²,⁷]dodeca-2,4,6-triene-10-carbonyl]pyrrolidin-2-yl]-2-methylbutanimidic acid
(1s)-2-[(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl 2-methylbut-2-enoate
(1s,3r,4s,5s,7r,8s,9r,12s,13s,16s)-16-(acetyloxy)-13-(furan-3-yl)-5-hydroxy-7-(2-methoxy-2-oxoethyl)-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-4-yl 3-methylbutanoate
1-[(12e)-12-ethylidene-10-{14-ethylidene-10-oxa-8,16-diazahexacyclo[11.5.2.1¹,⁸.0²,⁷.0¹⁶,¹⁹.0¹²,²¹]henicosa-2,4,6-trien-9-yl}-6-hydroxy-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6-trien-8-yl]ethanone
methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(1s,14r,15z)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
(1s)-2-[(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl (2z)-2-methylbut-2-enoate
methyl 2-[(3r,4r,5s)-4-[(1ar,3s,3ar,4r,5r,6r,7as)-4,5-bis(acetyloxy)-3-(furan-3-yl)-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-6-yl]-5-(acetyloxy)-2,2,4-trimethyl-7-oxooxepan-3-yl]acetate
(1s,2r,4s,5s,6r,7s,9r)-5-(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-4-{[(2e)-3-phenylprop-2-enoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate
2-hydroxy-2,6-dimethyl-8-[(2-oxochromen-7-yl)oxy]oct-6-en-3-yl 3-{4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-2-hydroxyphenyl}prop-2-enoate
(3s)-n-[(2r,3r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl]-3-amino-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}hexanimidic acid
(1r,2s,4r,5r,9s,10s,13s,14r,15r,17r)-15-[(1r)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
5-methoxy-2-(methoxymethyl)-6-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]-4-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]oxan-3-ol
(1r,4r,7s,9s)-4-benzyl-9-(3-{[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}indol-1-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(12s,14s,15s,17r,31s,33s,34s,36r,41s,42s)-14,33-diethyl-10,16,35-trioxa-8,19,29,38-tetraazatetradecacyclo[31.7.1.1⁸,¹².1¹⁴,¹⁹.0¹,⁹.0²,⁷.0⁹,³¹.0¹¹,²².0¹¹,²⁹.0¹⁵,¹⁷.0²³,²⁸.0³⁴,³⁶.0³⁸,⁴¹.0²²,⁴²]tritetraconta-2,4,6,23,25,27-hexaene
(1r,2s,3s,5s,8r,9r,10s,11s,13r,16s)-9,11,16-tris(acetyloxy)-5,8-dihydroxy-3-(2-hydroxypropan-2-yl)-6,10-dimethyl-14-oxatetracyclo[8.6.0.0³,⁷.0¹³,¹⁶]hexadec-6-en-2-yl benzoate
(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(1e)-2-[(1s,4r,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate
10-(beta-hydroxybutyryl)-10-deacetylbaccatin i
{"Ingredient_id": "HBIN000075","Ingredient_name": "10-(beta-hydroxybutyryl)-10-deacetylbaccatin i","Alias": "10-(\u03b2-hydroxybutyryl)-10-deacetylbaccatin i; 5beta,20-Epoxy-9-oxotax-11-en-1,2alpha,4,7beta,10beta,13alpha-hexol 2-benzoate 4-acetate 10-(3-hydroxybutyrate)","Ingredient_formula": "C33H42O12","Ingredient_Smile": "CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)OC(=O)CC(C)O","Ingredient_weight": "630.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT19245","TCMID_id": "31162;9864","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5318160","DrugBank_id": "NA"}
13-decinnamoyl-9-deacetyltaxchinin b
{"Ingredient_id": "HBIN001162","Ingredient_name": "13-decinnamoyl-9-deacetyltaxchinin b","Alias": "NA","Ingredient_formula": "C33H42O12","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C2(CC1O)C(C)(C)O)OC(=O)C)(CO4)OC(=O)C)OC(=O)C)C)O)OC(=O)C5=CC=CC=C5","Ingredient_weight": "630.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4850","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101995266","DrugBank_id": "NA"}
15-benzoyl-2-debenzoyl-7,9-dideacetyl-abeo-baccatin vi
{"Ingredient_id": "HBIN001624","Ingredient_name": "15-benzoyl-2-debenzoyl-7,9-dideacetyl-abeo-baccatin vi","Alias": "NA","Ingredient_formula": "C33H42O12","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2237","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7,9-deacetylbaccatin vi
{"Ingredient_id": "HBIN013002","Ingredient_name": "7,9-deacetylbaccatin vi","Alias": "NA","Ingredient_formula": "C33H42O12","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)O)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4725","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}